Abstract
Urocortin comprises a group of endogenously produced peptide hormones that belong to the corticotropinreleasing factor (CRF) family with promising future as potential drugs for the treatment of heart disease. Members of the urocortin family are known to act as potent regulators of cardiac and vascular functions, through the activation of the CRF receptors that are highly expressed in heart and peripheral tissues. Urocortin exhibits potent vasodilatory effects in arteries from different species. These effects have been related to its capability to regulate the intracellular Ca2+ concentrations ([Ca2+]i) by different molecular mechanism. Beside, urocortin increases heart contractility and evokes positive inotropic and lusitropic effects by mechanisms involving different kinases signalling pathways. Urocortin peptides have also the ability to protect the heart from ischemia and reperfusion injuries by their improvement of post-ischemic cardiac performances, which include the recovery of heart contraction, the prevention from intracellular Ca2+ overload and the reduction of cardiac cell death. Furthermore, heart protection by urocortin involves the regulation of the transcription of specific genes acting to minimize mitochondrial damage, cell death, and oxidative stress. This review summarizes some of the recent findings related to the molecular mechanism underlying the role of urocortin in both vascular and cardiac function.
Keywords: Urocortin, vascular smooth muscle relaxation, positive inotropism, cardioprotection.
Current Vascular Pharmacology
Title:New Insights into the Mechanisms Underlying Vascular and Cardiac Effects of Urocortin
Volume: 11 Issue: 4
Author(s): Ignacio Diaz and Tarik Smani
Affiliation:
Keywords: Urocortin, vascular smooth muscle relaxation, positive inotropism, cardioprotection.
Abstract: Urocortin comprises a group of endogenously produced peptide hormones that belong to the corticotropinreleasing factor (CRF) family with promising future as potential drugs for the treatment of heart disease. Members of the urocortin family are known to act as potent regulators of cardiac and vascular functions, through the activation of the CRF receptors that are highly expressed in heart and peripheral tissues. Urocortin exhibits potent vasodilatory effects in arteries from different species. These effects have been related to its capability to regulate the intracellular Ca2+ concentrations ([Ca2+]i) by different molecular mechanism. Beside, urocortin increases heart contractility and evokes positive inotropic and lusitropic effects by mechanisms involving different kinases signalling pathways. Urocortin peptides have also the ability to protect the heart from ischemia and reperfusion injuries by their improvement of post-ischemic cardiac performances, which include the recovery of heart contraction, the prevention from intracellular Ca2+ overload and the reduction of cardiac cell death. Furthermore, heart protection by urocortin involves the regulation of the transcription of specific genes acting to minimize mitochondrial damage, cell death, and oxidative stress. This review summarizes some of the recent findings related to the molecular mechanism underlying the role of urocortin in both vascular and cardiac function.
Export Options
About this article
Cite this article as:
Diaz Ignacio and Smani Tarik, New Insights into the Mechanisms Underlying Vascular and Cardiac Effects of Urocortin, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040009
DOI https://dx.doi.org/10.2174/1570161111311040009 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiplatelet Treatment in Stroke: New Insights
Current Pharmaceutical Design Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Recent Advances in the Discovery and Development of Marine Natural Products with Cardiovascular Pharmacological Effects
Mini-Reviews in Medicinal Chemistry Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Current Pharmaceutical Design MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Dietary Lutein and Zeaxanthin in the Prevention of Age-Related Macular Degeneration in the Elderly
Current Nutrition & Food Science Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Forkhead Genes: Their Role and Impact on Ocular Developmental Diseases
Current Genomics Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Characteristics and Clinical Applications of K201
Current Clinical Pharmacology "Heart Failure: Meeting the Challenges of Surveillance and Knowledge Translation in Resource-poor Settings"
Current Cardiology Reviews Bioadhesive Films as Drug Delivery Systems
Drug Delivery Letters Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium
Current Signal Transduction Therapy Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy